Select a Region North America


Chris Cameron, PhD

Senior Vice President, Value and Evidence


Clinical Trials, Data and Software, HEOR, Pricing, Reimbursement & Market Access, Regulatory, RWE

Dr. Chris Cameron is a global thought leader in health economics and outcomes research with over a decade of experience. Prior to joining EVERSANA, Chris was a partner at Cornerstone Research Group Inc., and lead of Health Economics at CADTH. He has also been a consultant decision scientist for ICER, a member of the Economic Guidance Panel at pCODR, and served on PMPRB Technical Panel on drug pricing guidelines in Canada. Chris is an adjunct (scholar) professor at Dalhousie University, and has authored over 100 peer-reviewed publications in many of the world’s top journals, including JAMA, Lancet, and BMJ. His research has been featured in the Globe and Mail and New York Times. He was recently named one of the most prolific authors in the world on indirect treatment comparisons, and was a co-author on the PRISMA NMA reporting guidelines.

Chris holds a bachelor’s degree in Mathematics and an MSc and PhD in Epidemiology where he was a Vanier Canada Graduate Scholar. He also completed a fellowship on real-world data analytics at Harvard University and FDA’s Sentinel Initiative, and the Oxford Artificial Intelligence Programme.

Articles by Chris Cameron, PhD

ISPOR 2020 WORKSHOP: Developing Global Indirect Treatment Comparison Programs for Market Access

DEVELOPING AND IMPLEMENTING AN INDIRECT TREATMENT COMPARISON (ITC) PROGRAM TO SUPPORT GLOBAL HEALTH TECHNOLOGY ASSESSMENT (HTA) AND REIMBURSEMENT SUBMISSIONS Virtual ISPOR 2020 | WEDNESDAY, May 20th, 2020 | 10:00 AM ET PURPOSE: This interactive workshop will examine the various indirect comparison methodologies that are available. Commonly used ITC methods such as network meta-analysis (NMA) and matching-adjusted indirect comparisons (MAIC) will be discussed using real-world case studies. Discussion leaders and international experts in ITC from Canada, US and Europe will describe methods to develop and implement global ITC strategies to support HTA and reimbursement submissions. The workshop will also provide guidance on selecting the appropriate ITC method to align with analytic objectives […]

ISPOR 2020 PODIUM: PSM and Bayesian Hierarchical Design Methods to Integrate Single-Arm Studies into NMAs in Lung Cancer

APPLICATION OF PROPENSITY SCORE MATCHING AND BAYESIAN HIERARCHICAL DESIGN METHODS TO INTEGRATE SINGLE-ARM STUDIES INTO NETWORK META-ANALYSES (NMAS): Opportunities and Pitfalls Illustrated in a Case Study Assessing Ablation/Radiation Therapies in Lung Cancer Virtual ISPOR 2020 | TUESDAY, May 19th, 2020 | 5:45-6:00 PM ET OBJECTIVES: Network meta-analyses (NMAs) generally include direct comparative evidence from randomized controlled trials (RCTs) and/or comparative observational studies; however, comparative evidence is limited in many disease/treatment areas. The objective of this analysis was to discuss opportunities and pitfalls associated with incorporating single-arm studies into NMAs, illustrated in a case study assessing the effectiveness of ablation/radiation therapies in lung cancer. METHODS: A systematic literature review was conducted […]

ISPOR 2020 PODIUM: Methodological Challenges with NMAs Assessing Long-term Efficacy in Psoriasis

METHODOLOGICAL CHALLENGES WITH CONDUCTING NETWORK META-ANALYSES ASSESSING LONG-TERM COMPARATIVE EFFICACY IN PSORIASIS- A CRITIQUE OF ASSUMPTIONS UNDERPINNING RECENT INDIRECT TREATMENT COMPARISONS Virtual ISPOR 2020 | TUESDAY, May 19th, 2020 | 5:30-5:45 PM ET OBJECTIVES: In network meta-analysis (NMA) of psoriasis trials, cross-over after an initial placebo-controlled period limits the connectivity of long-term evidence networks. We illustrate the challenges with conducting NMAs assessing efficacy beyond cross-over in psoriasis by critically appraising the assumptions underpinning recent long-term NMAs. METHODS: We compared three recent NMA studies (Armstrong et al. 2019, Sawyer et al. 2018, and Diels et al. 2017) assessing long-term (beyond 16 to 24 weeks) comparative efficacy in psoriasis and investigated how the three […]

Interested in scheduling a meeting or speaking event?


  • このフィールドは入力チェック用です。変更しないでください。